Sex hormone-binding globulin: not a surrogate marker for venous thromboembolism in women using oral contraceptives

Contraception

Volumn 78, Issue 3, 2008, Pages 201-203

  Stanczyk, Frank Z ^a   Grimes, David A ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; BIOLOGICAL MARKER; CLOFIBRATE; DANAZOL; DESOGESTREL PLUS ETHINYLESTRADIOL; DIANE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ENCAINIDE; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL PLUS GESTODENE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; FLECAINIDE ACETATE; GESTAGEN; IBOPAMINE; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT; PROSTACYCLIN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ARTICLE; DRUG SAFETY; ESTRADIOL BLOOD LEVEL; HUMAN; HYPERANDROGENISM; HYPERPROLACTINEMIA; ORAL CONTRACEPTION; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; TESTOSTERONE BLOOD LEVEL; VENOUS THROMBOEMBOLISM;

BIOLOGICAL MARKERS; CONTRACEPTIVES, ORAL, COMBINED; FEMALE; HUMANS; SEX HORMONE-BINDING GLOBULIN; VENOUS THROMBOEMBOLISM;

EID: 48649094375     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2008.04.004     Document Type: Article

References (31)

1. Odlind V., Milsom I., Persson I., and Victor A. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills?. Acta Obstet Gynecol Scand 81 (2002) 482-490
2. van Rooijen M., Silveira A., Hamsten A., and Bremme K. Sex hormone-binding globulin - a surrogate marker for the prothrombotic effects of combined oral contraceptives. Am J Obstet Gynecol 190 (2004) 332-337
3. van Vliet H.A., Frolich M., Christella M., et al. Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens. Hum Reprod 20 (2005) 563-568
4. Grimes D.A., and Schulz K.F. Surrogate end points in clinical research: hazardous to your health. Obstet Gynecol 105 (2005) 1114-1118
5. Kahn S.M., Hryb D.J., Nakhla A.M., Romas N.A., and Rosner W. Sex hormone-binding globulin is synthesized in target cells. J Endocrinol 175 (2002) 113-120
6. Rosner W. Plasma steroid-binding proteins. Endocrinol Metab Clin North Am 20 (1991) 697-720
7. Uriel J., Dupiers M., Rimbaut C., and Buffe D. Maternal serum levels of sex steroid-binding protein during pregnancy. Br J Obstet Gynaecol 88 (1981) 1229-1232
8. Westphal U. Steroid-protein interactions II (1986), Springer-Verlag, Berlin 320-322
9. Cavaliere H., Abelin N., and Medeiros-Neto G. Serum levels of total testosterone and sex hormone binding globulin in hypothyroid patients and normal subjects treated with incremental doses of L-T4 or L-T3. J Androl 9 (1988) 215-219
10. Beastall G.H., Cowan R.A., Gray J.M., and Fogelman I. Hormone binding globulins and anticonvulsant therapy. Scott Med J 30 (1985) 101-105
11. Rosenfield R.L. Plasma testosterone binding globulin and indexes of the concentration of unbound plasma androgens in normal and hirsute subjects. J Clin Endocrinol Metab 32 (1971) 717-728
12. Kopelman P.G., White N., Pilkington T.R., and Jeffcoate S.L. The effect of weight loss on sex steroid secretion and binding in massively obese women. Clin Endocrinol (Oxf) 15 (1981) 113-116
13. Haffner S.M., Katz M.S., Stern M.P., and Dunn J.F. The relationship of sex hormones to hyperinsulinemia and hyperglycemia. Metabolism 37 (1988) 683-688
14. Hammond G.L., Langley M.S., Robinson P.A., Nummi S., and Lund L. Serum steroid binding protein concentrations, distribution of progestogens, and bioavailability of testosterone during treatment with contraceptives containing desogestrel or levonorgestrel. Fertil Steril 42 (1984) 44-51
15. Darley C.R., Kirby J.D., Besser G.M., Munro D.D., Edwards C.R., and Rees L.H. Circulating testosterone, sex hormone binding globulin and prolactin in women with late onset or persistent acne vulgaris. Br J Dermatol 106 (1982) 517-522
16. Gershagen S., Doberl A., and Rannevik G. Changes in the SHBG concentration during danazol treatment. Acta Obstet Gynecol Scand Suppl 123 (1984) 117-123
17. Altman D.G. The scandal of poor medical research. BMJ 308 (1994) 283-284
18. Echt D.S., Liebson P.R., Mitchell L.B., et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 324 (1991) 781-788
19. WHO. Cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Report of the Committee of Principal Investigators. Lancet 2 (1980) 379-385
20. Califf R.M., Adams K.F., McKenna W.J., et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J 134 (1997) 44-54
21. Hampton J.R., van Veldhuisen D.J., Kleber F.X., et al. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Lancet 349 (1997) 971-977
22. Fleming T.R., and DeMets D.L. Surrogate end points in clinical trials: are we being misled?. Ann Intern Med 125 (1996) 605-613
23. Prentice R.L. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 8 (1989) 431-440
24. Albert J.M., Ioannidis J.P., Reichelderfer P., et al. Statistical issues for HIV surrogate endpoints: point/counterpoint. An NIAID workshop. Stat Med 17 (1998) 2435-2462
25. Stedman's medical dictionary. 27th ed. (2000), Lippincott, Williams and Wilkins, Philadelphia
26. Dorland's illustrated medical dictionary. 30th ed. (2003), Saunders, Philadelphia
27. Dinger J.C., Heinemann L.A., and Kuhl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception 75 (2007) 344-354
28. Bossuyt P.M., Reitsma J.B., Bruns D.E., et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin Chem 49 (2003) 7-18
29. Mammen E.F. Oral contraceptives and blood coagulation: a critical review. Am J Obstet Gynecol 142 (1982) 781-790
30. Winkler U.H. Blood coagulation and oral contraceptives. A critical review. Contraception 57 (1998) 203-209
31. Comp P.C. Thrombophilic mechanisms of OCs. Int J Fertil Women's Med Suppl 1 (1997) 170-176